As of 30 Sep 2026
| Holding | % of fund | Value | Shares |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 10.45% | ₹20.04 Cr | 1,10,321 |
| Divi's Laboratories Ltd. | 7.09% | ₹13.61 Cr | 14,648 |
| Eli Lilly And Co | 6.46% | ₹12.39 Cr | 1,116 |
| Apollo Hospitals Enterprise Ltd. | 5.25% | ₹10.08 Cr | 12,342 |
| Johnson & Johnson Ltd. | 4.45% | ₹8.53 Cr | 3,356 |
| Laurus Labs Ltd. | 4.44% | ₹8.52 Cr | 43,046 |
| Torrent Pharmaceuticals Ltd. | 4.38% | ₹8.39 Cr | 17,489 |
| Cipla Ltd. | 4.34% | ₹8.33 Cr | 61,907 |
| Max Healthcare Institute Ltd. | 4.19% | ₹8.04 Cr | 86,518 |
| Dr. Reddy's Laboratories Ltd. | 3.95% | ₹7.57 Cr | 61,404 |
The fund is rated 1 star. Taken together, the fund's movement relative to its index and annual fee of 1.1% place it behind most similar funds.
This index fund/ETF has a beta of 0.676%, and an expense ratio of 1.1%, giving it a 1.0 star rating, based on the principle that lower values of |1-beta| and expense ratio result in higher ratings.
Our score weighs long-term performance, risk and consistency — not just past returns.
As of 9 Nov 2026
As of 31 Oct 2026
Long Term Capital appreciation. Passive investment in equity and equity related securities replicating the composition of MSCI India Domestic & World Healthcare 45 Index, subject to tracking error.
The scheme seeks to invest in stocks comprising of the MSCI India Domestic & World Healthcare 45 Index with the objective to provide investment returns that, before expenses, closely corresponds to the returns equivalent to the index, subject to tracking errors.
Mutual funds are subject to market risk. Read all scheme documents carefully.
